Alcon drops 6% after trimming 2026 outlook
Reuters via Global Banking & Finance · · AI-summarised by FinFlash
Alcon shares fell about 6% by 10:05 GMT, heading for their worst session in six months, after the eye-care group narrowed guidance. Third-quarter net sales rose 5% to $2.72 billion, slightly short of forecasts, with implantables down 2%. Alcon now sees its markets growing around 3% in 2026, versus 3% to 4% before, and cut the top of its core EPS growth range to 14%. JPMorgan said a $58 million tariff refund flattered profit.
So What?
The guidance trim and reliance on a one-off refund weigh on the Swiss medtech name and the SMI. Investors will watch whether softer eye-care market growth spreads to peers.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.